<DOC>
	<DOCNO>NCT02919735</DOCNO>
	<brief_summary>Phase II clinical trial</brief_summary>
	<brief_title>Efficacy , Safety Tolerability CG428 Cutaneous Solution Chemotherapy Induced Alopecia ; Controlled Study ( ELAN )</brief_title>
	<detailed_description>The aim trial compare degree efficacy , safety tolerability CG 428 cutaneous solution versus placebo prevention chemotherapy induce alopecia ( CIA ) female patient metastatic cancer treat select regimen induce alopecia .</detailed_description>
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Adult female , age ≥ 18 year . Advanced stage cancer , require one follow prespecified chemotherapy regimen accord local guideline : weekly paclitaxel , weekly docetaxel , eribulin association weekly paclitaxel/docetaxel carboplatine . Healthy hair ( current alopecia scalp disease treatment ) . Life expectancy ≥ 6 month . Able use study treatment compliance protocol . Physical psychological ability participate . Negative serum pregnancy test within 14 day prior randomization premenopausal woman childbearing potential . Patients must agree shave head ( minimum ≥ 1 cm ) . Signed date informed consent . Other ongoing antineoplastic therapy investigational drug potential effect hair growth . Prior radiotherapy scalp residual alopecia . Known allergy hypersensitivity component CG 428 cutaneous solution ( include allium cepa ( onion ) , citrus , caffeine , theobromine ) . Preexisting alopecia significant scalp disease , may alter study treatment administration absorption . Concomitant use cold cap antihair loss treatment . Hair transplant .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Alopecia</keyword>
	<keyword>Hair</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Cancer</keyword>
</DOC>